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A protease-resistant Escherichia 
coli asparaginase with outstanding 
stability and enhanced anti-
leukaemic activity in vitro
Maristella Maggi1, Steven D. Mittelman2, Jean Hugues Parmentier2, Giorgio Colombo3, 
Massimiliano Meli  3, Jeannette Marie Whitmire4, D. Scott Merrell4, Julian Whitelegge5 & 
Claudia Scotti  1
L-Asparaginases (ASNases) have been used as first line drugs for paediatric Acute Lymphoblastic 
Leukaemia (ALL) treatment for more than 40 years. Both the Escherichia coli (EcAII) and Erwinia 
chrysanthemi (ErAII) type II ASNases currently used in the clinics are characterized by high in vivo 
instability, short half-life and the requirement of several administrations to obtain a pharmacologically 
active concentration. Moreover, they are sensitive to proteases (cathepsin B and asparagine 
endopeptidase) that are over-expressed by resistant leukaemia lymphoblasts, thereby impairing 
drug activity and pharmacokinetics. Herein, we present the biochemical, structural and in vitro 
antiproliferative characterization of a new EcAII variant, N24S. The mutant shows completely 
preserved asparaginase and glutaminase activities, long-term storage stability, improved thermal 
parameters, and outstanding resistance to proteases derived from leukaemia cells. Structural analysis 
demonstrates a modification in the hydrogen bond network related to residue 24, while Normal Mode-
based geometric Simulation and Molecular Dynamics predict a general rigidification of the monomer 
as compared to wild-type. These improved features render N24S a potential alternative treatment to 
reduce the number of drug administrations in vivo and to successfully address one of the major current 
challenges of ALL treatment: spontaneous, protease-dependent and immunological inactivation of 
ASNase.
L-Asparaginases (ASNases) were described as antiproliferative agents in the 1950s1. Their therapeutic mecha-
nisms rely on the removal of L-asparagine and L-glutamine from blood, taking advantage of the fact that most 
leukaemia cells are unable to de novo synthesize sufficient quantities of these amino acids2. ASNases are first line 
drugs for paediatric Acute Lymphoblastic Leukaemia (ALL). Presently, Escherichia coli (EcAII) type II ASNase, 
either in native or PEGylated form, is typically used as a first choice drug, while the Erwinia chrysanthemi (ErAII) 
enzyme is used only in cases of immune reactions to E. coli-derived ASNases. Unfortunately, ASNase-based ther-
apy has some limitations: (i) pancreas, liver and immune system impairment, (ii) high immunogenicity, (iii) 
low efficacy and higher toxicity in adult patients, and (iv) low stability in vivo3,4. In fact, both native proteins are 
characterized by low in vivo stability, resulting in short half-life and need for several administrations. Moreover, 
protein instability contributes to epitope unmasking, with an increased likelihood of antibody production and 
subsequent immune reactions5. Two lysosomal proteases, asparaginase endopeptidase (AEP) and cathepsin B 
(CTSB), further inactivate EcAII by hydrolysis, contributing to therapy failure6. AEP and CTSB are expressed 
by Philadelphia positive (Ph+) and iAMP21 leukaemia cells, two very aggressive and poorly responsive forms 
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of leukemia7–9, while microenvironment cells such as macrophages can express CTSB and contribute to ASNase 
degradation10. While PEGylation improves ASNase stability and pharmacokinetic/pharmacodynamics profiles, 
immunogenicity and CTSB hydrolysis still limit its use for the treatment of ASNase-inactivating tumors6.
Biochemically, bacterial type II ASNases are amidohydrolases (EC 3.5.1.1) that catalyze L-asparagine (L-Asn) 
hydrolysis to L-aspartic acid (L-Asp) and ammonia. With reduced efficiency, ASNases are also capable of deami-
nating L-glutamine (L-Gln), releasing L-glutamic acid (L-Glu) and ammonia. From the structural point of view, 
ASNases are homotetramers of roughly 130–140 kDa. The N-domain contains the active site flexible loop (resi-
dues 3–27), a peculiar structural element that acts as a lid closing on the active site upon substrate binding and 
that carries two essential catalytic residues (a Thr and a Tyr).
Site-directed mutagenesis is routinely used to build EcAII variants with improved features, mainly aimed at 
modulating the enzyme substrate specificity and immunogenicity, and at improving its stability11–14. The active 
site flexible loop is a critical region for all these aspects, and, particularly, residue Asn24, even though not directly 
involved in catalysis, plays a crucial role in stabilizing the enzyme active site, interacting mainly with the cata-
lytic T12 residue15. Moreover, Asn24 has been identified as primary cleavage site for both AEP and CTSB16. We 
designed an N24S mutation based on the assumption that this modification should lead to relevant changes in 
these interactions. Herein, we present the biochemical, structural and in vitro antiproliferative characterization 
of N24S, showing preserved activities, very much improved thermal and proteolytic resistance, and improved 
long-term cytotoxicity in vitro. These enhanced features provide a molecule potentially suitable to improve effi-
cacy, particularly in drug-resistant patients and/or relapsed ALL.
Results
N24S has preserved specific activities and kinetic parameters. Kinetic parameters (Table 1) of the 
recombinant wild-type (WT) and N24S were very similar to each other, and to the deposited values (BRENDA 
enzyme database17). Both enzymes had a hyperbolic response of activity versus both L-Asn and L-Gln increasing 
concentrations, and a stronger preference for L-Asn over L-Gln as a substrate.
N24S shows a high thermal resistance. Because in vivo ASNase activity is related to thermal stability18,19, 
we next evaluated the melting temperature (T50) of our mutant enzyme vs. WT. The T50 of N24S was significantly 
higher than WT EcAII (59 ± 2.2 vs. 49 ± 1.3 °C, p = 0.002, Fig. 1a). N24S was also more resistant to heat-induced 
unfolding, as demonstrated by a rightward shift in thermal shift analysis (Fig. 1b). N24S T0.5 (the temperature 
at which half of the protein was in an unfolded state) was also higher than the WT one (62.04 ± 0.10 °C vs. 
59.63 ± 0.62 °C, p < 0.001). Moreover, N24S had a slower unfolding kinetics than WT (5.3 vs. 7.5%/°C), and a 
higher initial unfolding temperature (57 vs. 51 °C).
N24S shows long-term stability upon storage. Protein degradation was monitored by SDS-PAGE 
analysis and Coomassie staining. Freshly prepared EcAII run in reducing conditions typically showed a single 
33 kDa band corresponding to the full-length, undegraded monomer (Fig. 2a, lane 3). Upon storage in the pres-
ence of water solution, progressive degradation and activities reduction occurred, while a 30 kDa band became 
predominant over time: in Fig. 2a, lane 2, a preparation preserved in Na-phosphate buffer at +4 °C for 83 days 
is shown. This behaviour was very consistent among different batches and not due to contaminating proteases20 
(data not shown). In fact, a qualitative test for proteases detection both on freshly purified and degraded protein 
solutions was performed. The test was based on the use of casein as a substrate and Folin-Ciocalteu as a detection 
dye21. In all cases, protein solutions were negative for proteases. Compared to the typical 7–10 days stability of 
WT in Na- phosphate at 4 °C, N24S was active for more than 9 weeks. It did not show any sign of degradation 
when preserved in PBS at +4 °C even after one year (Fig. 2b, lane 2), in contrast to the WT (Fig. 2b, lane 3). Both 
proteins in lyophilized form showed full stability after 1 year at −20 °C (data not shown). Though N24S showed 
long-term stability upon storage, the underlying mechanism needs to be clarified.
An aliquot of fully degraded EcAII WT was analyzed by native-PAGE in order to determine if, despite its 
progressive loss of activity, the tetrameric complex was maintained upon degradation. As shown in Fig. 2c, freshly 
purified EcAII ran as a single band with a molecular weight (MW) comprised between 100 and 150 kDa (lane 
3), while the fully degraded and inactive protein (lane 2) ran as a single species with a slightly lower MW (ca. 
100 kDa). The absence of other bands of different MWs suggests preservation of the tetrameric complex upon 
degradation. The fully degraded protein (Fig. 2d, lane 2) was not reactive towards the anti-HisTag antibody 
directed to the EcAII N-terminus 6xHisTag, suggesting removal of the N-terminal portion of the protein.
A solution containing a partially degraded EcAII WT was then analyzed by N-terminal sequencing to deter-
mine cleavage points. The obtained results showed that, apart from the full-length protein, a mixture of protein 
forms with an N-terminus starting within amino acids 25–30 was detected, indicating a complete removal of the 
flexible loop residues (3–27).
Variant
Specific Activity (U/mg) Km (mM) kcat (sec−1) Efficiency (kcat/Km)
L-Asn L-Gln L-Asn L-Gln L-Asn L-Gln L-Asn L-Gln
Wild-type 105.20 ± 8.14 0.89 ± 0.22 0.03 ± 0.01 3.95 ± 0.47 59.77 ± 4.63 0.51 ± 0.13 1975 0.13
N24S 103.50 ± 10.23 0.93 ± 0.20 0.03 ± 0.01 4.14 ± 0.33 58.81 ± 5.81 0.53 ± 0.012 1782 0.13
Wild-type* — — 0.04 ± 0.30 3.50 ± 0.50 49 ± 0.30 0.33 ± 0.20 1600 0.09
Table 1. Kinetic parameters of EcAII variants. Experiments are average ± SD of at least 2 independent 
experiments performed in triplicate. *Recombinant wild type EcAII described by14.
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N24S has a higher long-term cytotoxicity than the wild-type. In order to compare the in vitro 
anti-proliferative effect of EcAII WT and N24S to the commercial enzyme Elspar (Medac), cytotoxicity assays were 
performed against several human ALL cell lines (MOLT-4, REH, RS4;11 and SD1). EcAII WT and N24S showed a 
cytotoxic effect comparable to the commercial Elspar protein on all cell lines but SD1, where, unexpectedly, they had 
a nearly 4.30-fold higher cytotoxic effect at 3.0 U/ml (Table 2). Regarding long-term cytotoxicity, WT and N24S had 
the same effect on both SD1 and REH cells at 72 h. At 144 h, however, N24S had a 47.5% higher cytotoxicity on SD1 
cells than the WT (p = 0.000), while both ASNases had the same cytotoxicity on REH cells (Fig. 3a,b).
N24S is insensitive to SD1 cell proteases. EcAII WT, N24S and Elspar were incubated in the presence of 
SD1 cell lysate at 37 °C o.n. After incubation, samples were separated by SDS-PAGE and blotted onto a nitrocellu-
lose membrane. After Ponceau Red staining, a clear degradation band was evident in the WT and Elspar samples 
Figure 1. Thermal stability assays. (a) EcAII WT (circle) and N24S (triangle) thermal inactivation plot. Results 
are reported as residual activity percentage of heat-treated vs. untreated sample. Samples were incubated at 37 °C 
for 10 min and the residual activity was measured in the presence of 10 mM L-Asn. (b) Heat-induced melting 
curves of WT (continuous line) and N24S EcAII (dashed line). The horizontal dotted line is the reference line 
corresponding to an unfolded fraction value equal to 0.5. Melting curves were obtained by thermal shift analysis 
using CYPRO orange as a fluorescent dye. Unfolded fraction values are reported as procedure defined units 
(p.d.u.).
Figure 2. EcAII degradation pattern upon storage. (a) SDS-PAGE of EcAII after storage at +4 °C in Na-
phosphate. Lane 1: molecular weight standards; lane 2: degraded protein (83-days old); lane 3: freshly purified 
protein (1-day old). (b) SDS-PAGE of EcAII and N24S after 1 yr storage at +4 °C and in PBS buffer. Lane 1: 
molecular weight standards; lane 2: N24S; lane 3: wild-type. (c) Native-PAGE of fully degraded (lane 2) and 
freshly purified EcAII (lane 3). (d) Western blot analysis of fully degraded (lane 2) and freshly purified EcAII 
(lane 3) after native-PAGE. Full-length blot is presented in Supplementary Figure 3.
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and absent in the N24S sample (Fig. 4). The experiment was repeated 4 times with similar results. Protein masses 
were measured by low-resolution ESI-MS after treatment with cell extracts. The measured mass of ASNase before 
cleavage (35548 Da) was in good agreement with that calculated for the His-tagged monomer (calculated average 
mass 35546 Da). The measured mass of ASNase after cleavage (31963 Da) was consistent with an N-terminal 
cleavage at G28 (calculated average mass 31962 Da) within experimental error. A less abundant species at 
32116 Da was consistent with an N-terminal cleavage at T26 (calculated average mass 32118 Da). The observed 2 
amino acid steps from N24 might arise from N-exo-dipeptidase trimming after N-terminal processing.
N24S shows a global structural organization similar to EcAII wild-type. Single prismatic crystals 
of N24S were obtained in 100 mM HEPES, pH 7.5, 5% w/v PEG 8000, 4% v/v ethylene glycol, at 21 °C after 4 
days. The crystal described in the present paper had an approximate size of 300 × 35 × 30 µm and diffracted up to 




MOLT-4 0.005 29.92 ± 3.47 28.21 ± 1.35 28.85 ± 0.77
REH 3.0 55.21 ± 2.80 61.80 ± 6.52 58.8 ± 11.55
RS4;11 0.005 29.30 ± 5.57 24.0.3 ± 3.56 25.15 ± 1.39
SD1 3.0 19.88 ± 6.86 21.72 ± 4.96 84.51 ± 8.60
Table 2. Cytotoxicity of EcAII wild-type, N24S and Elspar. Experiments are average ± SD of at least 2 
independent experiments performed in triplicate.
Figure 3. Effect of WT EcAII and N24S on SD1 (a) and REH (b) cells. Data are the average ± SD of at least 3 
independent experiments performed in triplicate. Statistical significance (p < 0.05) was evaluated by one-way 
ANOVA and Tukey test. Untreated cells (Ctrl) were set as 100%.
Figure 4. Elspar, EcAII WT and N24S degradation by SD1 cell lysate (Ponceau Red staining). +/− indicates 
the presence or absence of cell lysate.
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asymmetric unit (ASU) contained 2 distinct intimate dimers (namely, A/C and B/D), which rebuilt the full bio-
logical tetramer (ACBD) by crystallographic symmetry (for clarity, in the following text Ser24(A) indicates Ser24 
of monomer A). Clear electron density (ED) corresponding to the L-Asp product was present in all 4 active sites 
of the ASU. Two of the 4 monomers (i.e., C and B) also presented clear electron density for residues belonging to 
the active site flexible loop (residues 3–27), while residues 16–27 were missing in monomers A and D. Overall, 
the monomers present in the ASU were similar (r.m.s.d. average of the main chain: 0.19 ± 0.05 Å, Supplementary 
Table 1). The overall structure of the N24S tetramer, the orientation and organization of critical catalytic residues, 
and of the L-aspartate product are highly similar to the WT one (r.m.s.d. 0.34 ± 0.01 Å, supplemental Tables 4–5 
and supplemental Fig. 1).
Local structural changes indicate a reorganization of internal and inter-monomer interactions 
in N24S. In the WT structures (e.g., 3ECA and 1NNS), the residue Asn24 side chain faces the near intimate 
monomer and acquires contacts with it through interactions with residue Asp281 (Fig. 5)15. Two different confor-
mations of residue Ser24 are visible in the two monomers (B and C), where ED for the loop was clearly available 
(Fig. 5b). In the conformation present in monomer B, the Ser24 Oγ group is oriented towards the inner part of 
the flexible loop. In the conformation present in monomer C, the Ser24 Oγ group is oriented towards the near 
intimate monomer (chain A) and acquires contacts with the main chain O of residue Ala282. The shortening 
of the residue 24 side chain in the mutant protein causes the loss of contacts with the side chain of D281 in the 
intimate dimer, while the presence of the Ser OH group weakens the bond compared to the one formed by the 
Asn NH2 group. The bond formed by Asp281(C) Oδ2 and Lys186(B) NHζ (Fig. 5) is also lost in the mutant struc-
ture. Molecular dynamics simulations on wild type and on N24S L-Asp-bound proteins show the presence of a 
persistent H-bond between Asn24(A) and Asp281(C) that is lost in the mutant structure in favour of two new 
intra-loop persistent H-bonds between Ser24(A) and Asp18(A) and Lys22(A) (Table 4). Analysis of the two pro-
teins in their apo form shows a similar behaviour consisting in the loss in the mutant of one inter-monomer per-
sistent H-bond (Asp24(A) - Ala282(C)) and the formation of two new persistent H-bonds, one intra-monomer 
(Ser24(A) - Lys22(A)) and one inter-monomers (Ser24(A) - Asp281(C)).
Normal Mode-based geometric Simulation and Molecular Dynamics show a general rigidifica-
tion of N24S. A general tendency towards rigidification of N24S (that is, a lower r.m.s.f.) with respect to the 
WT was observed by Normal Mode-based geometric Simulation (Supplementary Figure 2a, Table 5). The highest 
rigidification was registered for the 166–168 loop with a Δ r.m.s.f. between 1.15 and 1.38 Å. Protein motions anal-
ysis, using the lowest radius of gyration (ROG) as conformation choice criteria, showed a relevant variation in 520 
of the 1497 total conformations. Moreover, all the 520 variations had a lower r.m.s.d. (Δ comprised between −0.5 
and −1.11 Å) for N24S than for the wild-type (Supplementary Figure 2b, Table 5). Analysis of protein motions, 
5MQ5
Data collection
Space group C 2
Cell dimensions
a, b, c (Å) 152.0, 62.34, 142.27
α, β, γ (°) 90.0, 117.92, 90.0
Resolution (Å) 48.16–1.43 (1.43–1.50)
Rmerge 0.062 (1.24)
Mean I/σI 8.60 (0.60)
Completeness (%) 89.70 (57.90)
Redundancy 2.60 (2.0)
Refinement
Resolution (Å) 12.97–1.60 (1.66–1.60)
No. of reflections 275508 (27697)










Bond length (Å) 0.011
Bond angles (°) 1.0
Table 3. Crystallographic data and statistics for N24S. High resolution shell is shown in parenthesis.
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using the highest ROG as conformation choice criteria, showed that all the conformations had r.m.s.d. values 
lower for N24S (Δ range, −0.5/−1.19 Å) than for the wild-type (Supplementary Figure 2c, Table 5). Loop motion 
was evaluated for the more extended conformations (largest ROG, Supplementary Figure 2d). Only 3 residues 
had a r.m.s.f. higher for the mutant (i.e., residues 21 and 166–168, Δ range 0.7–0.8 Å), the other 50 residues, com-
prising residues 23–30, all had an r.m.s.f. lower for the mutant in a Δ range −0.5 and −1.7 Å (Table 5).
Molecular Dynamics (MD) simulations confirmed and extended these results. The atom-positional r.m.s.d. 
from the crystal structures of the WT and N24S proteins in both the apo and Asp-bound forms are displayed 
in Fig. 6. All simulations show r.m.s.d. values lower than 1.5 Å, consistent with the fact that no major structural 
distortion is taking place in the crystals.
To investigate protein flexibility and its relationships to mutation-induced stabilization, we calculated the 
r.m.s.f. for residues around their equilibrium positions during the simulations. In this case, the r.m.s.f. value 
was calculated for the different residues in each monomer, and then the values for corresponding residues in 
the different monomers were averaged to provide an approximate measure of protein flexibility. Next, we cal-
culated the difference r.m.s.f. between N24S and WT, by subtracting the averaged values of the corresponding 
residue positions. In Fig. 7a and b, negative values along the sequence indicate a rigidification in the mutant. The 
Figure 5. Comparison of H-bonds of Asn24 (EcAII WT, panel a) and of Ser24 (N24S, panel b). Only 
H-bonds predicted by PISA and different in the two structures are shown and are represented as dotted lines. 
Relevant residues are shown as sticks colored in green for the WT and in cyan for the N24S mutant. The two 
conformations of Ser24 Oγ in the N24S mutant are shown in purple (monomer B) or in red (monomer C). The 
L-Asp reaction product is shown for both structures and represented as sticks (yellow). For each residue the 
monomer to which it belongs is annotated as a capital letter in parentheses.
Protein Residue (Chain) Residue (Chain) Percentage of presence (%)
N24S + ASP Asp18(A) Ser24(A) 26.0
Asp18(A) Ser24(A) 21.4
Lys22(A) Ser24(A) 20.7
WT + ASP Asp281(C) Asn24(A) 29.1
N24S APO Lys22(A) Ser24(A) 20.8
Asp280(B) Ser24(A) 16.2
WT APO Ala282(C) Asn24(A) 24.8
Table 4. Persistent H-bonds. The data are reported for 1 single monomer, but in the case of N24S the same 
pattern is seen across all monomers.
Loop motions Residues with relevant r.m.s.f. Δ Residues with Δ r.m.s.f. >0.5 Å Residues with Δ r.m.s.f. <0.5 Å
Lowest ROG 139 of 326 14 of 139 125 of 139
Largest ROG 53 of 326 3 of 53 50 of 53
Protein motions Conformations with relevant r.m.s.d. Δ
Conformations with Δ 
r.m.s.d. > 0.5 Å
Conformations with Δ 
r.m.s.d. < 0.5 Å
Lowest ROG 520 of 1497 0 of 520 520 of 520
Largest ROG 787 of 1467 0 of 787 787 of 787
Table 5. Normal geometric-Mode Simulations. N24S residues (loop motions) or conformations (protein 
motions) with higher (Δ r.m.s.f. or d. > 0.5 Å) or lower (Δ r.m.s.f. or d. < 0.5 Å) than the WT.
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predominance of negative values shown in the histograms reporting the distribution of r.m.s.f.-differences indi-
cate a general rigidification of the mutant, both in the apo and in the bound states. Structural rigidification can 
aptly reverberate in structural stabilization and resistance to unfolding or degradation.
We then extended our analysis of mutation-induced dynamic rigidification to the global level, by calculating 
the fluctuations of pairwise amino acid distances on all possible residue pairs in the protein (Fig. 8)22–24. The same 
calculation was then carried out separately for each monomer. This calculation reports on the distribution of rigid 
vs. flexible substructures in the protein by evaluating the long-range coordination of residue pairs in the structure 
(the lower the distance fluctuations the higher the coordination between two residues). Groups of amino acids 
(even belonging to different domains) may respond to mutation by changing their long-distance coordination, 
coupled to a modulation of the inter domain rigid dynamics. All matrices exhibited a similar block character 
which reflects the presence of regions of small and large fluctuations of inter-residue distances corresponding 
to the various monomers. Nevertheless, N24S in the apo state, and to a lesser extent in the Asp-bound state, are 
characterized by a diffuse coordination (low fluctuations) pattern among residues that diffuses throughout the 
protein structure: extended coordination indicates an increased overall rigidity of the mutated tetramer. The 
observed global rigidification for the mutant can aptly be considered to oppose conformational changes that may 
guide the protein along unfolding pathways.
Finally, we analyzed the H-bonding patterns that characterize the active site in the two proteins. The most per-
sistent H-bonds are reported in Table 4. It is clear from the data that the N24S mutation modifies the H-bonding 
distribution favoring the formation of intramonomer interactions, compared to the WT case, where fewer 
H-bonds are established and mainly across monomers.
Removal of residues 1–29 in degraded EcAII reveals a new predicted epitope. In silico epitope 
prediction allows to highlight the presence of protein sequences able to induce an immune response in vivo 
according to bioinformatic algorithms. Degradation of the wild-type implies removal of the N-terminal loop, 
and exposure of an otherwise hidden patch of protein surface. The increased stability of the N24S mutant can 
prevent this exposure and the generation of antibodies directed towards this surface patch. Indeed, prediction on 
degraded EcAII (i.e. missing residues 1–29 or 1–24) by both Ellipro and DiscoTope allowed to highlight a novel 
epitope, present at the intimate dimer interface and involving residues 117–120, which is not predicted in the 
intact WT protein.
Discussion
ASNase-based therapy has an outstanding efficacy in paediatric ALL treatment25, but roughly 10% of treated 
patients are not responsive to the standard combination therapy and 10–20% of children in remission experience 
relapse within 5 years. Metabolic distress induced by L-Asn and L-Gln depletion, host immune response and 
ASNase limited stability in vivo are among the most important causes of therapy failure26. In fact, early develop-
ment of anti-ASNase antibodies is linked to allergic reactions and negative outcome even in the absence of allergic 
symptoms25,27. Beyond native immunogenic epitopes, tumour-released proteases can degrade ASNase, unmask-
ing new sites and increasing the risk of antibody production6. Because Asn24 is the primary EcAII CTSB and AEP 
cutting site6,15, we designed an N24S mutant to test if a shorter side chain preserving an oxygen group could lead 
to protease resistance and improved in vitro efficacy. Though enzymatically equivalent to the WT, N24S showed 
higher stability upon medium and long-term storage and the capacity of maintaining its functional folding in 
harsh thermal conditions. Investigation of the structural basis of these unique features evidenced that, as expected 
from the N24S catalytic properties, the enzyme active site was preserved in its architecture (Supplementary 
Figure 1). The shortening of the Ser24 side chain, however, was responsible for significant changes in the local 
bond network. These results are in accordance with the ones obtained by thermal shift analysis, reinforcing the 
hypothesis that the mutant improved stability is mainly linked to the active site loop structural stabilization. This 
moving structural element includes residues 3–27 and, beyond the mutated Asn24, essential residues for catalysis. 
Indeed, N24S structure motion for the active site flexible loop is less prominent than the WT one, especially in the 
region (amino acids 23–26) neighbouring the mutated residue. This increased loop rigidity could also contribute 
to the enhanced long-term stability of the protein and to a reduced immunogenicity. In fact, the loop seems to 
protect an interface epitope which could become accessible to the host immune system upon protein degradation.
Figure 6. RMSD (Å) as a function of simulation time (ns). Both the wild-type and the N24S mutant show 
oscillations below 1.5 Å, indicating no major structural distortion.
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The strict relationship between loop structural integrity and protein functionality is, in fact, confirmed by the 
observation that the spontaneous loss of enzyme activity is not related to random degradation, but to removal of 
the first 25–30 residues carrying the flexible loop. Sample contamination by proteases could not be considered 
the cause for several reasons: (i) there are no known proteases able to cut this kind of peptide in E. coli28; (ii) even 
though N24S and EcAII are prepared in similar ways, spontaneous degradation is consistently present only in 
the latter; (iii) generation of the 3 cleavage products detected by N-terminal sequencing (starting at amino acid 
Tyr25, Lys29 and Val30) would require three specific proteases. In this respect, simulation of protease cleavage by 
Expasy shows that the proteases able to cleave at 25 and 29 are not present in E. coli28 (Supplementary Material), 
but in Mammals; (iv) the absence of proteases in the protein sample was definitely demonstrated by incubation 
with casein.
Spontaneous cleavage of the peptide bond next to asparagine or aspartate in the presence of water is, in fact, 
a common undesirable reaction in stored proteins29. The pathway of this cleavage reaction is closely related 
to the one leading to deamidation of asparagine side chains and the isomerization of aspartate residues. This 
requires cyclization involving the side-chain carbonyl carbon of asparagine and the next amide NH group, result-
ing in a succinimide derivative that then hydrolizes to aspartic acid derivatives. Normally, this occurs through 
Figure 7. RMSF (Å) of N24S versus wild-type in (a) apo form and (b) ligand-bound. Negative values along the 
sequence indicate a rigidification in the mutant.
www.nature.com/scientificreports/
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pre-equilibrium deprotonation of the NH group next to the Asn or Asp residue. In case the latter is not available 
(for example in prolines or in the presence of bulky side chains), pre-equilibrium deprotonation of the amide 
group of asparagine is followed by a nucleophilic attack by the nitrogen atom of the amide anion on the peptide 
carbonyl carbon of the asparagine residue. This gives peptide chain cleavage.
In our case, the wild type protein indeed carries an Asn in the solvent exposed position 24, which is replaced 
by a Ser in the N24S mutant. Moreovoer, residue 25 is a Tyr, perfectly emboding the situation described above 
leading to peptide cleavage.
N24S exerts a 50% enhanced cytotoxicity compared to the wild-type in long-term exposure to protease secret-
ing SD1 leukaemia cells. Its outstanding resistance to protease cleavage compared to WT is at the core of the suc-
cessful performance on this cell line, representative of high-risk leukaemia clones. Protease secretion, particularly 
of AEP and CTSB7, is a known feature of Ph+ and iAMP21 ALL, both characterized by a poor outcome8,30. These 
two leukaemia forms account for 4–6% of total ALL cases and their therapy is at the moment an unmet need. For 
its features, N24S represents an ideal candidate for a new therapeutic strategy. Its resistance to AEP cleavage at 
sites C-terminal to an Asn residue derives from Asn24 removal. The latter also reduces the cooperative effect of 
the NY sequence pair (residues 24–25) normally favouring CTSB cleavage31.
At least three mechanisms seem therefore to be at the basis of N24S increased long-term stability: an increased 
chemical resistance to hydrolysis, a stabilization of the active site loop bond network, and a general rigidification 
of the monomer structure. The sequence modification is also responsible for increased protease resistance.
Improved protein stability has per se great potential for improving ALL therapy. N24S EcAII could be eas-
ily combined with innovative drug delivery technologies like GRASPA, which successfully reduces ASNase 
immunogenicity and improves its half-life32,33, or chemical modifications like PEGylation, which, in PEGaspase 
(Oncaspar), accounts for its improved stability in vivo and for its highly reduced immunogenicity34. Interestingly, 
Oncaspar is nevertheless still sensitive to CTSB degradation6 and, therefore, not ideal for the treatment of 
CTSB-overexpressing leukaemias.
Figure 8. Fluctuations of pairwise amino acid distances on all possible residue pairs. (a) N24S apoprotein; (b) 
N24S bound to aspartate; (c) wild-type apoprotein; (d) wild-type bound to aspartate.
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The improved features of N24S offer a wide spectrum of new uses for the drug. For example, ASNases efficacy 
in solid tumours has been shown to be discontinuous and highly tumour dependent35–37. Increased protease 
activity, including CTSB’s, in solid tumours, derives not only from the tumour mass, but also from the cells 
surrounding the tumour, with relevance in carcinogenesis and tumour metastasis38. ASNase in vitro activity has 
been reported against gastrointestinal, lung and breast cancers, and multiple myeloma39–41. Phase I and phase I-II 
clinical trials using PEGaspase were also conducted in adult patients with solid tumors40,42. However, a large por-
tion of the treated patients was not responsive to the treatment mainly because the active dose of the drug quickly 
decreased after a few administrations40,42. Proteolytic inactivation of the drug could be a valid explanation of its 
low efficacy. Additional studies on spontaneous and/or protease-mediated degradation of ASNase in cell culture 
media, animal and patient sera are therefore needed to evaluate the practicality of a protease resistant version of 
the enzyme in the treatment of solid tumours.
According to our observations, though in vivo data will be essential, N24S is potentially useful to counteract 
limitations (ii)-(iv) mentioned in the Introduction because of its increased stability, conditioning: (i) a reduction 
of immunogenicity due to the removal of one predicted epitope; (ii) a higher in vivo efficacy inferred from the 
improved in vitro one; (iii) a higher in vivo stability, as one mechanism of decay, beyond the antibody response, 
derives from the wild-type sensitivity to proteases.
In summary, our results show that N24S presents outstanding features for an improved ASNase-therapy: pre-
served functional parameters, improved long-term stability in culture and upon storage, preserved or improved 
IC50, and resistance to tumour-derived proteases. It appears therefore as a potentially suitable alternative to the 
present routinely used formulations to reduce administration frequency, but especially for the treatment of refrac-
tory, relapsing and adult patients.
Moreover, protease resistance of N24S could be exploited for the treatment of solid tumours over-expressing 
CTSB that have thus far shown little or absent in vivo sensitivity to ASNase-based treatments. Further in vivo 
studies will hopefully confirm the improved features of N24S and pave the way for a safer, more effective 
ASNase-based therapy in the clinics.
Materials and Methods
Cloning. The construct containing the Escherichia coli ansB gene (Reference sequence: NC_000913.243), 
devoid of the leader sequence (nt. 1–63) and with a 5’ sequence encoding a 6xHisTag, was amplified from a syn-
thetic version of the full-length gene (pMA EcAnsB, GeneArt). The obtained amplification product was used for 
cloning into the pET101/D-TOPO (Invitrogen) expression vector. The final construct was used as a template for 
site-directed mutagenesis.
The pET101/D-TOPO vector containing the WT or the N24S mutated ansB gene was used to transform 
Escherichia coli BL21(DE3) ΔansA/ΔansB cells, a BL21(DE3) derivative strain designed to lack E. coli endoge-
nous ansA and ansB genes.
Generation of the BL21(DE3) ΔansA/ΔansB strain. Intermediate strains and primer sequences used 
to generate the BL21(DE3) ΔansA/ΔansB strain are listed in Supplementary Tables 3 and 4, respectively. The 
upstream and downstream flanking regions of the ansA coding sequence from E. coli strain BL21(DE3) (DSM919) 
were joined together by splicing by overlap extension (SOE) PCR. Primers EC_ansA_SOE_upF_SphI and EC_
ansA_SOE_upR were used to amplify a 500 bp region upstream of ansA using genomic DNA from BL21(DE3), 
while primers EC_ansA_SOE_downF and EC_ansA_SOE_downR_XbaI were used to amplify the 500 bp region 
downstream of ansA. The products from the upstream and downstream amplification reactions were mixed and 
a SOE reaction was performed using the EC_ansA_SOE_upF_SphI and EC_ansA_SOE_downR_XbaI primers. 
The resulting 1 kb amplicon was subcloned into the pGEMT-Easy vector to generate pDSM1084. Similarly, the 
upstream and downstream flanking regions of the ansB coding sequence from E. coli strain BL21(DE3) were 
joined together by SOE PCR. Primers EC_ansB_SOE_upF_SphI and EC_ansB_SOE_upR were used to amplify 
a 500 bp region upstream of ansB using genomic DNA from BL21(DE3), while primers EC_ansB_SOE_downF 
and EC_ansB_SOE_downR_SphI were used to amplify the 500 bp region downstream of ansB. The products from 
the upstream and downstream amplification reactions were mixed and a SOE reaction was performed using the 
EC_ansB_SOE_upF_SphI and EC_ansB_SOE_downR_SphI primers. The resulting 1 kb amplicon was subcloned 
into the pGEMT-Easy vector to generate pDSM1085.
To enable DNA transfer through a DNA donor delivery system, the ans gene flanking regions were moved into 
the pCVD44244 vector and then transformed into the Sm10-λpir strain of E. coli. The pCVD442 vector confers 
ampicillin resistance and sucrose sensitivity. Briefly, pCVD442 and pDSM1084 were double digested with Sph I 
and Xba I, and the 1 kb fragment from pDSM1084 (containing the ansA flanking regions) and the pCVD442 back-
bone were gel purified and ligated. The ligation product was transformed into chemically-competent DH5α-λpir 
cells. Transformants were selected on LB plates supplemented with 100 µg/ml ampicillin (Amp100), and the cor-
rect plasmid was verified by restriction digest with Sph I and Xba I and by amplification with EC_ansA_SOE_
upF_SphI and EC_ansA_SOE_downR_XbaI primers. This strain was designated DSM1086. Next, pDSM1086 
was isolated from DSM1086 and was transformed into chemically-competent Sm10-λpir cells. Transformants 
were selected on LB plates supplemented with Amp100, and the correct plasmid was verified by restriction digest 
with Sph I and Xba I and amplification with EC_ansA_SOE_upF_SphI and EC_ansA_SOE_downR_XbaI 
primers. The resulting strain was designated as DSM1088. Using a similar strategy, pCVD442 and pDSM1085 
were digested with Sph I, and the 1 kb fragment from pDSM1085 (containing the ansB flanking regions) and 
the CIP-treated pCVD442 backbone were gel purified and ligated. The ligation product was transformed into 
chemically-competent DH5α-λpir cells. Transformants were selected on LB plates supplemented with Amp100, 
and the correct plasmid was verified by restriction digest with Sph I and amplification with EC_ansB_SOE_
upF_SphI and EC_ansB_SOE_downR_SphI primers. This strain was designated DSM1087. Next, pDSM1087 was 
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isolated from DSM1087 and was transformed into chemically-competent Sm10-λpir cells. Transformants were 
selected on LB plates supplemented with Amp100, and the correct plasmid was verified by restriction digest with 
Sph I and amplification with EC_ansB_SOE_upF_SphI and EC_ansB_SOE_downR_SphI primers. The resulting 
strain was designated at DSM1089.
To develop the ΔansA BL21(DE3) strain, strains DSM919 and DSM1088 were grown overnight in LB cultures 
supplemented with 50 μg/ml streptomycin (Sm50) and Amp100, respectively. Aliquots from each culture, corrected 
to obtain the same OD600, were pelleted and washed twice with LB. The pellets were resuspended in LB, combined, 
re-pelleted, and resuspended in LB. The resuspension was placed on an unsupplemented LB plate, and the cells 
were allowed to mate for 1 hour at 37 °C. The cells were then resuspended in LB and plated on LB agar plates sup-
plemented with Sm50 and Amp100 to select for BL21(DE3) cells that integrated the pDSM1088 plasmid through a 
single crossover event. The single colonies were further expanded on LB agar plates supplemented with Sm50 and 
Amp100. The streaks were then used to start LB liquid cultures without any antibiotic supplementation. Following 
overnight growth at 37 °C, the cultures were sub-cultured into LB. Once the sub-cultures were turbid, varying 
dilutions of the cultures were plated on L-broth plates supplemented with 10% sucrose. Resulting colonies were 
expanded on 10% sucrose L-broth agar plates and screened using the Ec_ansA_Far_F and Ec_ansA_Far_R prim-
ers, which produce a 2 kb band when the ansA coding region has been successfully deleted. DSM1092 was iden-
tified through this method and the region sequenced using primers Ec_ansA_Farseq_F and Ec_ansA_Farseq_R, 
which confirmed the deletion of the ansA gene. Using the same method described above, strains DSM919 and 
DSM1089 were mated to develop the ΔansB strain, which was screened using the Ec_ansB_Far_F3 and Ec_ansB_
Far_R3 primers, producing a 1.6 kb band when the ansB coding region has been successfully deleted. The deletion 
was further confirmed through sequencing with primers Ec_ansB_Farseq_F and Ec_ansB_Farseq_R, and the 
strain was designated at DSM1093.
To develop the ΔansA/ΔansB BL21(DE3) double mutation strain, strains DSM1092 and DSM1089 were 
grown overnight in LB cultures supplemented with Sm50 and Amp100, respectively. Aliquots from each culture, 
corrected to obtain the same OD600, were pelleted and washed twice with LB. The pellets were resuspended in 
LB, combined, re-pelleted, and resuspended in LB. The resuspension was placed on an unsupplemented LB plate, 
and the cells were allowed to mate for 1 hour at 37 °C. The cells were then resuspended in LB and plated on 
LB agar plates supplemented with Sm50 and Amp100 to select for BL21(DE3) ΔansA cells that integrated the 
pDSM1089 plasmid through a single crossover event. The single colonies were further expanded on LB agar 
plates supplemented with Sm50 and Amp100. The streaks were then used to start LB cultures without any anti-
biotic supplementation. Following overnight growth at 37 °C, the cultures were sub-cultured into LB. Once the 
sub-cultures were turbid, varying dilutions of the cultures were plated on L-broth plates supplemented with 10% 
sucrose. Colonies were expanded on the 10% sucrose L-broth agar plates and screened using the Ec_ansB_Far_F3 
and Ec_ansB_Far_R3 primers, which produce a 1.6 kb band when the ansB coding region has been successfully 
deleted. DSM1096 was identified through this method and sequenced using primers Ec_ansB_Farseq_F and 
Ec_ansB_Farseq_R to confirm the deletion of the ansB gene. Additionally, the deletion of the ansA gene was 
re-confirmed by sequencing using primers Ec_ansA_Farseq_F and Ec_ansA_Farseq_R.
Protein over-expression and purification. Protein over-expression was obtained according to Studier45. 
Recombinant proteins were purified by a two-steps chromatographic method that consisted in: nickel affinity 
chromatography and anionic exchange at pH 7.4 (for details, see supplemental Methods). Fractions positive for 
the enzymatic activity and pure to homogeneity were used for the following experiments. Proteins to be used for 
cytotoxicity assays were dialyzed versus PBS (0.01 M Na/K-phosphate buffer, 0.0027 M KCl and 0.137 M NaCl, pH 
7.4). For crystallization, N24S was dialyzed versus 30 mM Tris-HCl pH 8.0.
L-asparaginase and L-glutaminase activity assays. In order to determine ASNase and L-glutaminase 
activities, two methods were employed: a spectrophotometric one, using the coupled reaction catalyzed by glu-
tamic acid dehydrogenase (GADH), and a colorimetric one, using Nessler’s reagent (for details, see supplemental 
Methods).
One Unit of L-Asparaginase is defined as the amount of enzyme needed to convert 1 µmole of substrate into 
the product in the experimental conditions.
Cell lines. Human Acute Lymphoblastic Leukaemia (ALL) cells employed for the experiments are listed in 
supplemental Table 3. Human Acute Lymphoblastic Leukaemia cells (MOLT-4, SD1, REH, RS4;11) were grown 
in RPMI 1640 complete media (10% Fetal Bovine Serum, 2 mM L-glutamine, 50 μg/ml gentamicin). Cells were 
passaged every other day and cultured in a humidified incubator at 37 °C in the presence of 5% CO2.
Cytotoxicity evaluation. In order to compare the cytotoxicity of the recombinant EcAII WT and N24S pro-
teins to the one of the commercial Elspar enzyme (Medac), 1 × 105 cells were plated in 200 µl complete medium. 
Elspar was used as an internal control as the commercial protein has the same formulation of the drug used in 
the clinics and, as opposite to the recombinant EcAIIs, Elspar has no histidine tag. Lyophilized ASNase proteins 
were resuspended in complete medium and were added to the wells at a final concentration near the IC50 value 
for each cell line46. Each experiment was done in triplicate and repeated at least 3 times on different days. Trypan 
blue exclusion-dye count was done at 72 h and only living cells were counted.
To evaluate the improved stability of N24S lacking the main protease-recognition site16, its long-term cytotoxic 
effect was evaluated. SD1 and REH cell lines were chosen as model systems for the study, as SD1 cells over-express 
proteases, while REH cells do not. 1 × 105 cells were plated in 1.5 ml complete medium in a 24-well plate. Cells 
were treated with 0.5 U/ml (SD1) or 1 U/ml (REH). Cell viability was measured by trypan blue living-cell exclu-
sion dye at 72 h and 144 h. Data were expressed as percentage of living cells vs. control.
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Protein stability assays. Protein stability was assessed as residual activity (T50) and by thermal shift (T0.5). 
To determine the T50, the enzyme in Na-phosphate 50 mM pH 7.4 was incubated at different temperatures (range, 
37–70 °C) for 10 min. After incubation, the enzyme solution was cooled on ice and the enzyme activity meas-
ured by nesslerization. The T50 value was determined using the Temperature Melting Plot for Sigma Plot (SPSS 
Inc.). The treated enzyme residual activity was expressed as the percentage of activity of the heat-treated sample 
versus the untreated one. A thermal shift assay was performed using a MiniOpticon real time system (Bio Rad). 
Samples (0.5–1.5 mg/ml) in PBS buffer were mixed with 20X SYPRO orange dye (Invitrogen) in a final volume of 
50 μl. Samples were centrifuged and heated from 25 to 95 °C at 1 °C or 0.5 °C/min. Fluorescence was monitored 
at 517 nm. Raw data were normalized so that a value of 1 corresponds to completely unfolded protein. From the 
obtained curve, the T0.5 for each protein was extrapolated.
Statistical analysis. Long-term cytotoxicity data were analyzed by one-way ANOVA and Tukey test. The 
normal distribution for each data group was systematically verified by Shapiro-Wilk test47 and p values above 0.05 
were considered significant for normally distributed data. Each experiment was repeated 3 times and in triplicate 
for each condition (n = 9); p-values < 0.05 were considered significant. Thermal stability data were analyzed by 
T-test. Experiments were repeated 3 times for T50 determination and 6 times for T0.5; p-values < 0.05 were con-
sidered significant.
Western blot analysis. For Western blot analysis, proteins were transferred from within the gel to a PVDF 
0.22 µm membrane (Millipore). The blocked membrane was incubated with an HRP-conjugated anti-HisTag anti-
body (Sigma) diluted 1:7000.
N-terminal sequencing. In order to determine the N-terminal sequence of partially degraded EcAII WT 
protein, the Edman method was employed48. Briefly, after automated Edman degradation, phenylthiohydan-
toin(PTH)-derivates were separated by reverse-phase HPLC and the retention time was compared to a previously 
obtained standard curve of PTH-amino acids. The analysis was done on our behalf at the Laboratory of Proteins 
Primary Structure Analysis - “Centro grandi strumenti”, University of Pavia. For the analysis, partially degraded 
protein solution pure to homogeneity was provided at a concentration of 6.8 nM in PBS buffer. The solution was 
directly loaded onto a biphasic column connected to an automatic sequencer (HP G1000A, Agilent). After 12 
degradation cycles, data were analyzed.
Intact protein Mass Spectrometry. Samples previously prepared for SDS-PAGE were precipitated with 
chloroform/methanol and analyzed by liquid chromatography-mass spectrometry (LC-MS), as described previ-
ously49. Briefly, water was added to a final volume of 100 µL followed by 300 µL methanol and then 100 µL chloro-
form with mixing. An additional 200 µL water was then added to induce phase separation and the sample vortex 
mixed for 1 min. The protein precipitate was brought to the interface by centrifugation at 15,000 × g for 2 min. 
The upper phase was discarded and 300 µL methanol added prior to mixing the single organic phase. The protein 
precipitate was recovered by centrifugation at 15,000 × g for 2 min, the supernatant removed and the pellet dried 
at room temperature and pressure for 5 min. The pellet was dissolved in 70% formic acid and immediately injected 
onto an equilibrated reverse-phase column (Agilent PLRP/S, 150 × 2 mm, 300 Å, 5 µm, 40 °C). The column was 
equilibrated in 95% buffer A (0.1% TFA in water), 5% buffer B (0.05% TFA, 50% isopropanol, 50% acetonitrile) at 
200 µL/min for 20 min prior to sample injection and initiation of a linear gradient, 5% B at 5 min, 90% B at 55 min. 
The column eluent was directed to an electrospray-ionization source (Ionmax, Thermo) on a linear ion-trap mass 
spectrometer operated in positive ion mode (LTQ, Thermo) and scanned from 600–2000 m/z. The asparaginase 
peak was the only discernable peak in the LC-MS run and was deconvoluted using Magtran software. Mass accu-
racy on the LTQ typically gives better than 0.02% error on protein molecular weight determinations.
Protease sensitivity test. Confluent SD1 cells were collected by centrifugation (3500 rpm, 4 °C, 
5 min) and washed twice with PBS. The washed cell pellet was resuspended in lysis buffer (50 mM trisodium 
acetate buffer, pH 4.5, 5 mM DTT) using a 1 × 106 cells:0.1 ml buffer ratio. Cells were lysed by 4 cycles of 
freeze-thawing at −80 °C. Cell lysate was clarified by centrifugation (8000 rpm, 10 min, 4 °C) and whole pro-
tein extract was quantified by bicinchoninic acid assay (BCA, Pierce). The final reaction mixture volume was 
50 μl and contained: 100 μg cell lysate (only for treated samples) and 4 μg ASNase. After 24 h incubation at 
37 °C protein separation in denaturing and reducing conditions was performed by electrophoresis using a pre-
cast gradient 4–12% polyacrylamide gel (Bolt® gel, ThermoFisher Scientific). Proteins were transferred onto 
a nitrocellulose membrane using an iBlot® 2 device (ThermoFisher Scientific). The membrane was stained 
using Ponceau Red dye. Beyond EcAII wild type and N24S, also commercial Elspar was tested for proteases 
sensitivity as it was already used in previous similar experiments6,50 and, mainly, as it has the same formulation 
of the drug used in the clinics.
Crystallization. Escherichia coli type II ASNase N24S mutant was purified as reported above. The pure pro-
tein fraction was dialyzed versus 30 mM Tris-HCl, pH 8.0 and used for crystallization. Crystallization attempts 
were carried out using a sparse-matrix screening from Molecular Dimensions (MD1-03). The crystals were grown 
at 21 °C using the sitting-drop vapour diffusion method and by mixing equal volumes of mother liquor and 4 mg/
ml protein solution in a 2 µl drop. The original crystallization condition contained 100 mM HEPES, pH 7.5, 10% 
w/v PEG 8000, 8% v/v ethylene glycol. In order to improve crystal quality the condition was optimized varying 
buffer pH and precipitants concentration. Upon cryo-mounting on nylon loops, crystals to be analyzed by X-ray 
were soaked into 100 μM L-aspartic acid (L-Asp) dissolved in mother liquor for 10 min.
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Structure solution. X-ray data were collected at 100 K, 0.98 Å at beamline ID-29 at the European Synchrotron 
Research Facility (ESRF), Grenoble, France51. Data were integrated with Mosflm52 and merged with SCALA53. 
The space group was determined with POINTLESS53. The structure was solved by molecular-replacement with 
PHENIX-MR54 and using an intimate dimer of E. coli WT asparaginase (PDB ID: 3ECA)55 as a search model. 
Structure refinement was done with PHENIX-REFINE56 starting from an initial model deprived of ligand and 
of residues of the active-site flexible loop (residues 8–35). At each refinement run, residues were added manually 
where clear electron density was present. Ligands were added with PHENIX-LIGAND FIT and using L-aspartic 
acid as a search model54. Ramachandran statistics after refinement were the following: 98.58% lay in the favoured 
region, 1.42% in the allowed region and no outliers were present.
Normal Mode-based geometric Simulations. The crystallographic structures of monomer A from WT 
(1NNS) and monomer B from N24S (5MQ5) in complex with the L-aspartate product, and hence in the more 
compact conformation, were used for Normal Mode-based geometric simulations (NMSim)57. Loop motion was 
analyzed by small scale motions, whole protein motions were analyzed both with the lowest and largest radius of 
gyration (ROG) using default parameters (http://cpclab.uni-duesseldorf.de/nmsim/main.php). 0.5 Å was chosen 
as the ΔÅ cut off for relevance considering the structures high atomic resolution (1.95 Å WT and 1.60 Å N24S), 
the elevated number of simulation cycles (e.g., 500) and the average Δ (0.46 Å).
Molecular Dynamics simulations. WT and N24S L-Asparaginase were studied with all atom Molecular 
Dynamics (MD) simulations in the apo state and bound to Aspartate. Simulations of the bound forms were 
started from the respective crystal structures of WT (PDB ID: 3ECA) and N24S (PDB ID: 5MQ5) while starting 
structures for the apo forms were generated by simply deleting the coordinates of the ligand from the respective 
crystals.
We performed energy minimization of all the starting structures with AMBER1658 in explicit solvent (TIP3P 
water model59) using the FF14SB force field60 with a steepest descent method (3 × 103 steps), followed by a run 
in conjugate gradient algorithm (7 × 103 steps). After minimization, we heated the system from 0 to 300 K in the 
NVT ensemble over 25000 MD steps with a timestep of 2 fs. After the heating process, the simulation was run for 
50 ps (2 fs timestep) in the NPT ensemble (Berendsen barostat, Langevin temperature control with γ = 2 ps−1) 
using the SHAKE algorithm to constrain all the hydrogen-containing bonds61.
All production simulations were performed in the same condition of the last equilibration part; we carried out 
MD simulations of the crystal structures of WT and N24S ASNase at 300 K (100 ns each). Calculations of Root 
Mean Square Deviation (RMSD) and Root Mean Square Fluctations (RMSF) were performed using the tools 
available in the AMBER suite.
Protein internal dynamics. In order to analyze the impact of the N24S mutation on the internal dynamics 
properties of ASNase that can be related to global structural stabilization, we made use of the previously intro-
duced distance fluctuation analysis. For each MD trajectory in different bound states, we computed the matrix of 
distance fluctuations, in which each element of the matrix corresponds to the DF parameter:
⟨ ⟨ ⟩⟩ ⟩= −DF (d dij ij ij 2
where dij is the (time-dependent) distance of the Cα atoms of amino acids i and j and the brackets indicate the 
time-average over the trajectory. This parameter is invariant under translations and rotations of the molecules 
and, unlike the covariance matrix, does not depend on the choice of a particular protein reference structure. The 
DF matrix can be used to assess the intrinsic flexibility/rigidity of the proteins, and how these properties change 
upon mutation.
The DF was calculated for any pair of residues during the trajectory. This parameter characterizes residues 
that move in a highly coordinated fashion, and it is actually able to reflect the presence of specific coordination 
patterns. Proteins that are highly coordinated may show enhanced stability22,62,63.
Epitope prediction. The tetrameric EcAII WT structure (PDB: 3ECA), either full-length or missing residues 
1–24 or 1–29, was used for epitope prediction using the online, open source software ElliPro64 and Discotope65. 
Protein truncation at amino acid 24 was chosen to simulate CTSB and AEP cleavage; truncation at amino acid 
29 was instead chosen according to N-terminal sequencing results for degraded EcAII. Default parameters and a 
score threshold equal to 0.5 were used to identify relevant epitopes. A similar analysis was performed on the N24S 
mutant structure (PDB: 5MQ5).
Equipment and settings. For Fig. 2, all images were acquired using an EPSON DX4050 scanner at 300 
dpi. Panels were assembled using Microsoft Power point. The blot image reported in panel d was cropped and 
brightness was adjusted across the whole image (full-length, unmodified blot is presented in Supplementary 
Figure 3). For Fig. 4, the image was also acquired using an EPSON DX4050 scanner at 300 dpi. The image mode 
was changed from RGB color to Grayscale using Adobe Photoshop 6.0. Full-length, unmodified blot is presented 
in Supplementary Figure 4.
Data Availability. The N24S structure is available in the Protein Structure Database under ID 5MQ5. N24S 
is covered by patent filing number PCT/EP2016/076994.
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